Business Context and Reporting Period
AVITA Medical, Inc. filed a Form 8-K dated March 22, 2023, reporting corporate governance matters. The company is a medical device business; this filing does not provide operating or financial results.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
AVITA entered into an engagement letter with Robert McNamara, who is scheduled to join the Board effective April 1, 2023. Proposed compensation, subject to shareholder approval, includes annual cash compensation of $70,000, an initial equity grant valued at $210,000, and annual equity compensation valued at $105,000. Committee compensation, if applicable, will be negotiated separately.
Material Changes Versus the Prior Comparable Period
- Robert McNamara was appointed as a new independent, non-executive director, serving through the 2023 Annual Meeting of Stockholders.
- The Board had not yet determined whether to appoint Mr. McNamara to any committees.
- The company entered into a standard-form indemnification agreement with Mr. McNamara.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or business outlook. The principal disclosed contingency is that the stated director cash and equity compensation is subject to shareholder approval. The filing states that Mr. McNamara has no reportable family relationship, appointment arrangement with another person, or material related-party transaction.
The 2023 Annual Meeting of Stockholders is scheduled for June 6, 2023, at 3:00 p.m. Pacific Daylight Time, corresponding to June 7, 2023, at 8:00 a.m. Australian Eastern Standard Time, via live audio webcast.
Important Facts to Verify
- Verify shareholder approval of Mr. McNamara’s proposed cash and equity compensation.
- Verify the final composition of Board committees and any additional committee compensation.
- Verify Mr. McNamara’s service commencement and continuation through the 2023 Annual Meeting.
- Review the engagement letter and related press release filed as Exhibits 10.1 and 99.1.
- Confirm the date and webcast details for the 2023 Annual Meeting.